WASHINGTON D.C. — The Food and Drug Administration (FDA) on Monday unveiled a fresh approval pathway designed to accelerate the development of individualized therapies for ultra-rare diseases, a move heralded by officials as a potential turning point for patients with conditions lacking viable treatment options.
The initiative, dubbed the “plausible mechanism pathway,” aims to streamline the approval process for targeted treatments, including gene editing and RNA-based therapies, where traditional randomized controlled trials are often impractical due to the limited number of patients affected. The announcement, made during a press conference at the Department of Health and Human Services (HHS) headquarters, featured the case of an infant in the Philadelphia area diagnosed with carbamoyl-phosphate synthase 1 deficiency (CPS1), a rare genetic disorder.
HHS Secretary Robert F. Kennedy Jr. And FDA Commissioner Martin Makary, MD, MPH, presented the framework as a shift towards a more biologically aligned regulatory approach. “Under the framework we are announcing today, one well-controlled clinical investigation, supported by confirmatory evidence, can support approval,” Kennedy stated. The FDA’s draft guidance, issued jointly by the Center for Biologics Evaluation and Research and the Center for Drug Evaluation and Research, outlines the agency’s intention to approve or authorize personalized treatments based on “substantial evidence of effectiveness, and safety.”
The successful treatment of the infant with CPS1 at the Children’s Hospital of Philadelphia (CHOP) served as a model for the new protocol. Rebecca Ahrens-Nicklas, MD, PhD, director of the CHOP Gene Therapy for Inherited Metabolic Disorders Program, and Kiran Musunuru, MD, PhD, MPH, a cardiologist, geneticist and gene editor at the University of Pennsylvania and co-director of the Orphan Disease Center, collaborated on the personalized intervention. Musunuru explained that the therapy utilizes a “GPS-like” component that can be reprogrammed to target different genes, allowing for individualized treatments for a range of liver-centered diseases.
“We realized we could do this over and over again, individualizing the therapy to many patients with liver-centered diseases by just changing the GPS again and again, to correct each patient’s [genetic] misspelling,” Musunuru said during the press conference.
The FDA’s proposed pathway will incorporate five key elements: identifying molecular or cellular abnormalities, targeting the underlying alteration, utilizing natural history data, demonstrating successful application of the technology, and proving clinical benefit. The protocol as well includes stipulations for FDA approval and post-marketing analyses.
Makary emphasized the significant unmet needs within the rare disease community, noting that approximately 30 million Americans are affected. “For too long, they have been under-recognized, their conditions under-funded,” he said. “Our system is built for common diseases, not for rare ones.”
Ahrens-Nicklas highlighted the challenges of translating promising early trial results into widespread access, stating, “Promising science too often stalls before it reaches patients. The biggest hurdle is moving from a first-in-human trial to regulatory approval.” She stressed the importance of clear and consistent regulatory guidance, acknowledging that individualized genetic therapies do not fit the traditional drug development model.
Ahrens-Nicklas also urged researchers and developers to maintain meticulous data collection, emphasizing that “Every single piece of data from every patient is priceless.”
The Wyanoke Group, the parent company of Healio, SLACK Incorporated, and Vindico Medical Education, was not directly mentioned in connection with the FDA announcement, but Healio published coverage of the event on February 23, 2026.
